Andexanet alfa and heparin resistance in cardiac surgery: Experiences and risks associated with the reversal of direct oral anticoagulants

This publication has 9 references indexed in Scilit:

• Andexanet alfa in acute aortic syndrome: first UK experience
  European Journal of Cardio-Thoracic Surgery, 2023
• Evolving Trends in Consumption of Direct Oral Anticoagulants in 65 Countries/Regions from 2008 to 2019
  Drugs, 2023
• Heparin Insensitivity and Thrombotic Risk Associated With Sequential Uses of Prothrombin Complex Concentrate and Andexanet Alfa for Apixaban Reversal During Acute Type A Aortic Dissection Repair: A Case Report
  A&A Practice, 2022
• Hemoadsorption of Rivaroxaban and Ticagrelor during Acute Type A Aortic Dissection Operations
  Annals of Thoracic and Cardiovascular Surgery, 2022
• Intraoperative Off-Label Reversal of Apixaban by Andexanet Alfa while on VA-ECMO Immediately After Emergent Surgery for Acute Type A Aortic Dissection
  Journal of Cardiothoracic and Vascular Anesthesia, 2021
• Administration of Andexanet Alfa for Direct Factor Xa Inhibitor Reversal Precludes Therapeutic Heparinization for Cardiopulmonary Bypass
  Blood, 2019
• Difficult Intraoperative Heparinization Following Andexanet Alfa Administration
  Clinical Practice and Cases in Emergency Medicine, 2019
• Andexanet Alfa for Urgent Reversal of Apixaban Before Aortic Surgery Requiring Cardiopulmonary Bypass: A Case Report
  A&A Practice, 2019
• Insight into the incidence of acute aortic dissection in the German region of Berlin and Brandenburg
  International Journal of Cardiology, 2017